计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| L126277-5mg |
5mg |
现货 ![]() |
| |
| L126277-10mg |
10mg |
现货 ![]() |
| |
| L126277-50mg |
50mg |
期货 ![]() |
|
| 英文别名 | AC-32839 | NCGC00343768-01 | AKOS027422721 | Q27088510 | 71803L5F4S | EX-A426 | RABUSERTIB [WHO-DD] | D10397 | 2-(3,4-dihydroxyphenyl)-3,5,6,7-tetrahydroxy-chromen-4-one | BCP9000873 | BCPP000178 | BL166662 | 2-(3,4-dihydroxyphenyl)-8-beta-D-glucopyranosy |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | LY2603618 |
| 生化机理 | 强效和选择性Chk1抑制剂(IC50 = 7 nM)。抑制Chk1自磷酸化。在G2 / M期诱导细胞周期停滞,并诱导肺癌细胞的DNA损伤反应。当与培美曲塞组合使用时,抑制小鼠NSCLC异种移植物的生长。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 丝氨酸/苏氨酸蛋白激酶 Chk1 抑制剂 |
| 产品介绍 |
Y2603618是一种选择性Chk1抑制剂,具有潜在的抗肿瘤活性。Phase 2。A selective Chk1 inhibitor. LY2603618 is a selective Chk1 inhibitor with potential anti-tumor activity. Phase 2. |
| 纯度 | ≥98% |
| ALogP | 1.4 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | 1-[5-bromo-4-methyl-2-[[(2S)-morpholin-2-yl]methoxy]phenyl]-3-(5-methylpyrazin-2-yl)urea |
| INCHI | 1S/C18H22BrN5O3/c1-11-5-16(27-10-13-8-20-3-4-26-13)15(6-14(11)19)23-18(25)24-17-9-21-12(2)7-22-17/h5-7,9,13,20H,3-4,8,10H2,1-2H3,(H2,22,23,24,25)/t13-/m0/s1 |
| InChi Key | SYYBDNPGDKKJDU-ZDUSSCGKSA-N |
| Smiles | CC1=CC(=C(C=C1Br)NC(=O)NC2=NC=C(N=C2)C)OCC3CNCCO3 |
| Isomeric SMILES | CC1=CC(=C(C=C1Br)NC(=O)NC2=NC=C(N=C2)C)OC[C@@H]3CNCCO3 |
| 分子量 | 436.3 |
| Reaxy-Rn | 39808750 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=39808750&ln= |
| 溶解性 | 溶于DMSO, 最高浓度 (mg/mL): 8.73, 最高浓度(mM): 20 |
|---|---|
| 分子量 | 436.300 g/mol |
| XLogP3 | 1.400 |
| 氢键供体数Hydrogen Bond Donor Count | 3 |
| 氢键受体数Hydrogen Bond Acceptor Count | 6 |
| 可旋转键计数Rotatable Bond Count | 5 |
| 精确质量Exact Mass | 435.091 Da |
| 单同位素质量Monoisotopic Mass | 435.091 Da |
| 拓扑极表面积Topological Polar Surface Area | 97.400 Ų |
| 重原子数Heavy Atom Count | 27 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 486.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 1 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | L126277 |
| 1. Dai Y, Grant S. (2010) New insights into checkpoint kinase 1 in the DNA damage response signaling network.. Clin Cancer Res, 16 (2): (376-83). [PMID:20068082] |
| 2. Govindan R. (2011) Summary of presentation from the targeted therapy in lung cancer meeting.. J Thorac Oncol, 6 (11 Suppl 4): (S1757). [PMID:22005528] |
| 3. King C, Diaz H, Barnard D, Barda D, Clawson D, Blosser W, Cox K, Guo S, Marshall M. (2014) Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.. Invest New Drugs, 32 (2): (213-26). [PMID:24114124] |